Mayo Clinic

International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community

Retrieved on: 
Friday, April 12, 2024
FDA, International Myeloma Foundation, University, Mayo Clinic, Cancer, Multiple myeloma, International, University of Navarra, Safety, MRD, Progression-free survival, Doctor of Philosophy, ODAC, Disease, Patient, IMF, Commissioner, Harvard Medical School, Quality of life, Dana–Farber Cancer Institute, Pharmaceutical industry

This means that the FDA may approve multiple myeloma drugs in the development pipeline much sooner.

Key Points: 
  • This means that the FDA may approve multiple myeloma drugs in the development pipeline much sooner.
  • To date, many myeloma drug approvals take 9-12 years and must demonstrate a progression-free survival of 5-8 years.
  • With MRD testing as an early endpoint in clinical trials, researchers can reliably predict progression-free survival and overall survival for multiple myeloma patients, making it a precise early endpoint.
  • He cited the IMF’s collaboration with the i2TEAMM (or, the International Independent Team for Endpoint Approval in Multiple Myeloma).

HDI Announces Winners of the 2024 HDI Awards

Retrieved on: 
Wednesday, May 1, 2024
Software, Human Resources, Consulting, Professional Services, Technology, Education, Training, Other Technology, CO, Mayo Clinic, City, Unisys, Supervisor, Innovation, HDI, Colorado Convention Center, Support, XLA, ITIL, Organization, WBM, Printed circuit board

The winners were announced at SupportWorld Live , which is taking place April 27 - May 2 at the Colorado Convention Center in Denver, CO.

Key Points: 
  • The winners were announced at SupportWorld Live , which is taking place April 27 - May 2 at the Colorado Convention Center in Denver, CO.
  • The 2024 HDI Award winners:
    HDI has selected Rae Ann Bruno, President, Business Solutions Training, Inc, HDI trainer, consultant, speaker and partner to receive the HDI Lifetime Achievement Award.
  • “Congratulations to the winners of the 2024 HDI Awards.
  • All of the winners showcase the best of the best of our industry.”
    To learn more about HDI’s Global Service and Support Awards, click here .

Surescripts Launches Third Season of Its Award-Winning Podcast There’s A Better Way

Retrieved on: 
Wednesday, May 1, 2024
Public Policy, Government, Practice Management, Pharmaceutical, Managed Care, General Health, Health, Healthcare Reform, Health Technology, FDA, Professional, Organization, Mayo Clinic, HHS, Human services, Marketing, EHR, Health care, Customer experience, Patient safety, Patient, Surescripts, Gold, American Telemedicine Association, MPP, Season, Better Way, EHNAC, Pharmacist, Management

Surescripts®, the nation’s leading health information network, launched the third season of its award-winning podcast, There’s a Better Way: Smart Talk on Healthcare and Technology.

Key Points: 
  • Surescripts®, the nation’s leading health information network, launched the third season of its award-winning podcast, There’s a Better Way: Smart Talk on Healthcare and Technology.
  • Listen to There’s a Better Way: Season 3 trailer .
  • Surescripts introduced There’s a Better Way: Smart Talk on Healthcare and Technology in July 2022.
  • Both season one and season two were recognized by the Association of Marketing and Communication Professionals, receiving the 2022 Gold MarCom Award and the 2023 Platinum MarCom Award, respectively.

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class Iop-lowering Drug Candidate for Glaucoma

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, General Health, Health, Clinical Trials, Mayo Clinic, Osprey, Safety, EVP, Biochemistry, IOP, OHT, Hyperaemia, Therapy, Intraocular pressure, Patient, Trabecular meshwork, Ocular hypertension, General partnership, NTG, MBA, OAG, Molecular biology, Glaucoma, Ophthalmology, Overalls, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.
  • Proceeds from the financing will support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP).
  • “Qlaris is dedicated to developing new mechanisms of action that target unaddressed parameters within IOP regulation, an area of critical need.
  • Qlaris has the potential to demonstrate the importance of targeting EVP in the ongoing QLS‑111 Phase II trials and we look forward to the data from this innovative drug candidate.”

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
Thursday, April 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Retrieved on: 
Wednesday, April 10, 2024
Mayo Clinic, Cancer, Genomics, Hospital, Esophageal cancer, Proteomics, Insurance, Partnership, Doctor of Philosophy, Documentation, Clinical professor, Patient, CPT, Prophase, Endoscopy, EAC, Health, GERD, Risk assessment, Medical imaging

Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.

Key Points: 
  • Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
  • Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
  • ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
  • Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.

Clarapath Forms Strategic Collaboration with Mayo Clinic to Advance Pathology Tissue Processing

Retrieved on: 
Tuesday, April 23, 2024
Technology, Other Health, Health, Oncology, Robotics, Health Technology, Medical Devices, Software, Artificial Intelligence, Hardware, Electronic Design Automation, Education, Mayo Clinic, Laboratory, Safety, Anatomical pathology, Medical laboratory, Research, Pathology, Intelligence, Automation, Patient, Histology, Organization, Medical imaging

Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.

Key Points: 
  • Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.
  • The strategic collaboration combines Clarapath’s innovative tissue solution and domain experts with the clinical insights and expertise of Mayo Clinic.
  • “We are thrilled to collaborate with Mayo Clinic to advance the modernization of anatomic pathology,” said Eric Feinstein, CEO of Clarapath.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

Retrieved on: 
Wednesday, April 17, 2024
Cardiology, Telemedicine, Virtual Medicine, General Health, Health, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, USD, Mayo Clinic, Investment, Telehealth, Hand, Doctor, B2C, ECG, Imperial College London, SHL, Growth, SIX Swiss Exchange

In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength.

Key Points: 
  • In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength.
  • In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to remote cardiac care.
  • In the United States, SHL made significant strides in its direct-to-consumer strategy, prioritizing promotion of its SmartHeart® ECG technology.
  • Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape.

Paragonix LUNGguard System Shown to Reduce Post-Transplant Complications in Lung Transplant Recipients

Retrieved on: 
Wednesday, April 10, 2024
General Health, Health Technology, Health, Medical Devices, Consensus, FDA, Mayo Clinic, MCS, Research, Transport, Patient, Temperature, Medical imaging

The study compares conventional ice storage to the Paragonix LUNGguard system.

Key Points: 
  • The study compares conventional ice storage to the Paragonix LUNGguard system.
  • The analysis revealed that advanced lung preservation technology with the Paragonix LUNGguard favorably influences post-transplant outcomes, including reductions in primary graft dysfunction, the use of invasive MCS interventions, and improvement in renal function.
  • The 259 ice storage cases were unable to capture temperature data, and investigators noted that ice storage is empirically 0ºC.
  • For more information, visit paragonix.com
    The Paragonix LUNGguard™ (LUNGguard™) is intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs.

PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN

Retrieved on: 
Thursday, April 25, 2024
Mayo Clinic, Diagnosis, LP, Woman, Health, Production board, Bloating, Physician, Pelvic pain, Face, Northwestern University, Emory University, Nursing

DALY CITY, Calif., April 25, 2024 /PRNewswire/ -- PinkDx, Inc., an early-stage company focused on positively impacting the health of women throughout their life journey, today launched with $40 million in Series A financing. The company will use the funds to pursue its vision of identifying unmet medical needs that are unique to women, addressing them with scientific rigor, and providing answers that have an immediate, positive impact on their lives. The company will use a broad and deep scientific approach to test development, focusing initially on gynecological cancers.

Key Points: 
  • The company will use the funds to pursue its vision of identifying unmet medical needs that are unique to women, addressing them with scientific rigor, and providing answers that have an immediate, positive impact on their lives.
  • The financing was co-led by Catalio Capital Management, LP, and The Production Board.
  • PinkDx will initially focus on improving the diagnostic outcomes for women who have vague symptoms that may signal a gynecological cancer.
  • Prior to joining PinkDx, Dr. Cowan served as head of Medical Affairs for Mirvie and before that as medical director for Hologic's Diagnostics division.